Triple threat before surgery: could a new combo wipe out stomach cancer cells?
NCT ID NCT05941481
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests whether giving a three-part treatment before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. The treatment combines an immunotherapy drug (tislelizumab) with standard chemotherapy and a short course of radiation. The goal is to see if this approach can completely eliminate the tumor before surgery, potentially leading to better long-term results. The trial enrolls adults with specific stages of the disease who are healthy enough for surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (PD-1 antibody) combined with chemotherapy (capecitabine and oxaliplatin) and hypofractionated radiotherapy
What this could lead to
If successful, this approach could increase the chance of complete tumor removal during surgery and improve long-term survival for patients with locally advanced gastric cancer.
What could go wrong
This is a small Phase 2 trial, so results may not apply broadly. Combining treatments raises risks of side effects like immune reactions, fatigue, or digestive issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Comparing LADG vs TLDG for Gastric Cancer Qualit NCT05541783
- ASP2138 for Gastric Cancer Trial (NCT07673887)
- Emotional Distress & Immunotherapy in Gastric Ca NCT07662070
- ENDURANCE: Nivolumab for Esophagogastric Cancer NCT07663786
- TRK-950 for Gastric Cancer Trial (NCT06038578)
- Sleep & Immunotherapy Response in Stomach Cancer NCT07662005
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, 210009, China